You searched for lung cancer | Page 73 of 166

FDA Approves FoundationOne CDx as Companion Diagnostic to Detect NTRK Fusions Across All Solid Tumors

Posted by Laurie Bonner | Oct 24, 2020 | Cancer, Molecular Diagnostics |

The tissue-based comprehensive genomic profiling test is currently approved as a companion diagnostic for more than 20 targeted therapies.

InterVenn Biosciences IDs Potential Covid-19 Susceptibility Markers

Posted by Melanie Hamilton-Basich | Oct 20, 2020 | Covid 19, Mass Spectrometry |

The study demonstrates differential glycoproteomic profiles among covid-19-symptomatic and asymptomatic patients.

‘Coming into Their Own’: FDA Approval of Liquid Biopsy Tests Puts Early, Less Invasive Cancer Detection in Broader Reach

Posted by Laurie Bonner | Oct 8, 2020 | Cancer |

Simple blood tests to replace painful, invasive biopsies for cancer diagnosis will soon become more common after several recent FDA approvals, according to a report in USA Today.

Large Prospective Lung Cancer Study to Be Presented at ESMO

Posted by Melanie Hamilton-Basich | Sep 14, 2020 | Lung Cancer, Molecular Diagnostics |

Idylla reduced EGFR mutation testing turnaround time by more than a week versus reference methods for patients with NSCLC.

FDA Approves First NGS-Based CDx for RET Fusion-Positive NSCLC

Posted by Melanie Hamilton-Basich | Sep 11, 2020 | Lung Cancer |

Thermo Fisher Scientific’s Oncomine Dx Target Test simultaneously evaluates 23 genes clinically associated with NSCLC.

Search Results for: lung cancer

FDA Approves FoundationOne CDx as Companion Diagnostic to Detect NTRK Fusions Across All Solid Tumors

InterVenn Biosciences IDs Potential Covid-19 Susceptibility Markers

‘Coming into Their Own’: FDA Approval of Liquid Biopsy Tests Puts Early, Less Invasive Cancer Detection in Broader Reach

Large Prospective Lung Cancer Study to Be Presented at ESMO

FDA Approves First NGS-Based CDx for RET Fusion-Positive NSCLC

Recent Posts

Clinical Lab Products

Our Parent Company

Key Resources

Helpful Links